Abstract:Today, persistent and uncontrolled inflammation is appreciated to play a pivotal role in many diseases, such as cardiovascular diseases, neurodegenerative diseases, metabolic syndrome and many other diseases of public health concern (e.g. Coronavirus Disease 2019 (COVID-19) and periodontal disease). The ideal response to initial challenge in humans is a self-limited inflammatory response leading to complete resolution. The resolution phase is now widely recognized as a biosynthetically active process, governed by a superfamily of endogenous chemical mediators that stimulate resolution of inflammatory responses, namely specialized proresolving mediators (SPMs). Because resolution is the natural ideal response, the SPMs have gained attention. SPMs are mediators that include ω-6 arachidonic acid-derived lipoxins, ω-3 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)-derived resolvins, protectins and maresins, cysteinyl-SPMs, as well as n-3 docosapentaenoic acid (DPA)-derived SPMs. These novel immunoresolvents, their biosynthetic pathways and receptors have proven to promote resolution of inflammation, clearance of microbes, reduce pain and promote tissue regeneration via specific cellular and molecular mechanisms. As of 17 August, 2020, PubMed.gov reported >1170 publications for resolvins, confirming their potent protective actions from many laboratories worldwide. Since this field is rapidly expanding, we provide a short update of advances within 2-3 years from human and preclinical animal studies, together with the structural-functional elucidation of SPMs and identification of novel SPM receptors. These new discoveries indicate that SPMs, their pathways and receptors could provide a basis for new approaches for treating inflammation-associated diseases and for stimulating tissue regeneration via resolution pharmacology and precision nutrition.

Specialized pro-resolving mediators - Key players in resolution

Specialized pro-resolving mediator network: an update on production and actions

Pro-resolving lipid mediators are leads for resolution physiology

Specialized Proresolving Mediators for Therapeutic Interventions Targeting Metabolic and Inflammatory Disorders

Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus

Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators

Specialized pro-resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease

Resolvins, Specialized Proresolving Lipid Mediators, and Their Potential Roles in Metabolic Diseases

Resolvins and protectins in the termination program of acute inflammation

New Advances in Targeting the Resolution of Inflammation: Implications for Specialized Pro-Resolving Mediator GPCR Drug Discovery

Specialized Pro-Resolving Lipid Mediators: Endogenous Roles and Pharmacological Activities in Infections

Role of Specialized Pro-Resolving Lipid Mediators in Pulmonary Inflammation Diseases: Mechanisms and Development

Low-dose pro-resolving mediators temporally reset the resolution response to microbial inflammation

Is Lipid Metabolism of Value in Cancer Research and Treatment? Part II: Role of Specialized Pro-Resolving Mediators in Inflammation, Infections, and Cancer

Specialized pro-resolving lipid mediators: A new class of non-immunosuppressive and non-opioid analgesic drugs

Advance in Pro-Resolution Lipid Mediators and Mechanisms of Inflammation Resolution

SPMs exert anti-inflammatory and pro-resolving effects through positive allosteric modulation of the prostaglandin EP4 receptor

Specialized Pro-Resolving Mediators as Resolution Pharmacology for the Control of Pain and Itch

Advances in the Chemistry and Biology of Specialised Pro-Resolving Mediators (SPMs)

Specialized Pro-resolving Mediator Improves Vascular Relaxation via Formyl Peptide Receptor-2

Maresins: anti-inflammatory pro-resolving mediators with therapeutic potential.